Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA087687

Local Sample ID:	V156
Subject ID:	SU001298
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Age Or Age Range:	4-8 months
Gender:	Male and female
Human Ethnicity:	Mainly Caucasian
Human Trial Type:	RCT

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001313
Treatment Summary:	The pregnant women were enrolled in a double-blind, randomized controlled trial (DB-RCT)3. At enrollment during pregnancy week 22-26, the women were randomly assigned in a 1:1 ratio to receive 2.4 g per day of n−3 long-chain polyunsaturated fatty acids (LCPUFAs) in triacylglycerol form from fish oil capsules containing 55% eicosapentaenoic acid (20:5n–3, EPA) and 37% docosahexaenoic acid (22:6n–3, DHA (Incromega TG33/22, Croda, Health Care) or placebo in the form of lookalike olive oil capsules, containing 72% n–9 oleic acid and 12% n−6 linoleic acid (Pharma-Tech A/S). The women continued taking the daily supplement until 1 week after delivery, where they visited the research unit with their child. A subgroup of the pregnant women (n=623) also participated in another DB-RCT with a nested 2x2 factorial design in which they were assigned to 2400 IU of vitamin D per day or placebo from pregnancy week 22-26 till 1 week postpartum on top of the recommended pregnancy supplement of 400 IU/d; i.e. the women received 2800 vs. 400 IU/d of vitamin D, which did not significantly affect the offspring’s risk of developing asthma

Treatment ID:

TR001313

Treatment Summary:

The pregnant women were enrolled in a double-blind, randomized controlled trial (DB-RCT)3. At enrollment during pregnancy week 22-26, the women were randomly assigned in a 1:1 ratio to receive 2.4 g per day of n−3 long-chain polyunsaturated fatty acids (LCPUFAs) in triacylglycerol form from fish oil capsules containing 55% eicosapentaenoic acid (20:5n–3, EPA) and 37% docosahexaenoic acid (22:6n–3, DHA (Incromega TG33/22, Croda, Health Care) or placebo in the form of lookalike olive oil capsules, containing 72% n–9 oleic acid and 12% n−6 linoleic acid (Pharma-Tech A/S). The women continued taking the daily supplement until 1 week after delivery, where they visited the research unit with their child. A subgroup of the pregnant women (n=623) also participated in another DB-RCT with a nested 2x2 factorial design in which they were assigned to 2400 IU of vitamin D per day or placebo from pregnancy week 22-26 till 1 week postpartum on top of the recommended pregnancy supplement of 400 IU/d; i.e. the women received 2800 vs. 400 IU/d of vitamin D, which did not significantly affect the offspring’s risk of developing asthma